Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Multiple Myeloma
Multiple Myeloma
Elotuzumab-Based Triplet Regimen Stops Progression of High-Risk Smoldering Multiple Myeloma
Wayne Kuznar
Read More
Multiple Myeloma
The Evolution of Survivorship Care in Multiple Myeloma
John A. Welz, MPH
Read More
Multiple Myeloma
Three-Drug Regimen with Daratumumab a New Standard of Care for Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Read More
Multiple Myeloma
Targeting CD38, Isatuximab Produces Impressive Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Read More
Multiple Myeloma
Multiple Myeloma Therapy in 2015: “An Extraordinary Moment in Oncology”
Dana Taylor
Read More
Multiple Myeloma
All-Oral Regimen May Become a New Standard of Care in Advanced Multiple Myeloma
Dana Taylor
Read More
Multiple Myeloma
Consistent Benefit Over Time in Elotuzumab Studies
Dana Taylor
Read More
Multiple Myeloma
Daratumumab Improves Overall Survival in Multiple Myeloma
Dana Taylor
Read More
Multiple Myeloma
Pomalidomide plus Low-Dose Dexamethasone Combination Likely to Be Cost-Effective
Read More
Multiple Myeloma
Dissecting the Treatment Costs of Newly Diagnosed Myeloma in First 2 Years
Read More
1
2
3
4
5
6
Page 3 of 6
Results 21 - 30 of 52